Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.68 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.62 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430477 | 0.91 | NTRK1 (0.75) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1430503 | 0.91 | NTRK1 (0.75) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1430966 | 0.91 | NTRK1 (0.75) | NTRK1NTRK3NTRK2 | |
| SCHEMBL13623597 | 0.88 | NTRK1 (0.64) | NTRK1 | |
| SCHEMBL1431295 | 0.88 | NTRK1 (0.70) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1431151 | 0.87 | NTRK1 (0.63) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1430679 | 0.87 | NTRK1 (0.64) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1431061 | 0.86 | NTRK1 (0.60) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1431062 | 0.86 | NTRK1 (0.60) | NTRK1NTRK3NTRK2 | |
| SCHEMBL1431500 | 0.86 | NTRK1 (0.60) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | claimed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | claimed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | claimed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | claimed |
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | NTRK1 23/4885NTRK3 6/4885NTRK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.